

# Optimizing affordability

Breakout Group 5

Bettina Kraus on behalf of the group

2024-05-30

# Optimizing affordability – Discussion points

- **Guidelines agnostic of cost vs. incorporating health-economic aspects**
  - International guidelines should represent the gold standard based on available science vs. national committees to implement including cost evaluation and clinical impact
    - how can ESC support national societies?  
E.g. by facilitating exchange, by providing support to health economic experts in the local guideline panels
- **Establish priority recommendations per disease**
  - to guide national societies in their local evaluation
  - Including de-implementation of “historical” treatment recommendations based on low levels of evidence
- **Ways to assess affordability**
  - Short term cost vs. long-term savings
  - In situations of competing affordabilities within CV medicine and vs other specialties
  - And in use of drugs that treat and/or prevent more than one disease

# Optimizing affordability – Suggested Recommendations

- ESC to encourage (request?) national societies to use quality indicators and contribute to ESC registries
- ESC to establish priority recommendations (do's and don'ts) per disease
- ESC to facilitate support to national societies on their health-economic assessments
- ? CRT working group to assess how to change ways of assessing affordability